Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

被引：22

作者：

Park, Jae H. ^{[1
]}

Chung, Stephen S. ^{[1
]}

Durham, Benjamin ^{[2
]}

Chung, Young Rock ^{[3
]}

Scott, Sasinya ^{[2
]}

Getta, Bartlomiej ^{[2
]}

Kim, Eunhee ^{[2
]}

Saven, Alan ^{[4
]}

Stone, Richard M. ^{[5
]}

Rai, Kanti R. ^{[6
]}

Grever, Michael R. ^{[7
]}

Altman, Jessica K. ^{[8
]}

Rosen, Neal ^{[9
]}

Levine, Ross L. ^{[2
]}

Berger, Michael ^{[10
]}

Tallman, Martin S. ^{[1
]}

Abdel-Wahab, Omar ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA

[4] Scripps Hlth, La Jolla, CA USA

[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[6] North Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA

[7] Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA

[8] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[9] Mem Sloan Kettering Canc Ctr, Pharmacol, New York, NY 10021 USA

[10] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.682.682

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Vemurafenib As First Treatment of Hairy Cell Leukemia
Cheng, Gregory
Cheng, Gym
Chan, Natalie Pui Ha
Wong, Chris
Wong, Raymond S.
BLOOD, 2014, 124 (21)
[32] EXPERIENCE WITH VEMURAFENIB IN THE TREATMENT OF HAIRY CELL LEUKEMIA
Sari, E.
Baghy, K.
Kovalszky, I.
Boedoer, C.
Rajnai, H.
Csomor, J.
Nagy, Z.
Demeter, J.
HAEMATOLOGICA, 2015, 100 : 706 - 706
[33] Kinase activity in vemurafenib-sensitive and resistant BRAF-mutant melanoma cells.
Risberg, Karianne
Roe, Kathrine
Ree, Anne H.
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[34] Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
Teresa Delgado-Goñi
Teresa Casals Galobart
Slawomir Wantuch
Deimante Normantaite
Martin O. Leach
Steven R. Whittaker
Mounia Beloueche-Babari
British Journal of Cancer, 2020, 122 : 72 - 81
[35] Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
Delgado-Goni, Teresa
Galobart, Teresa Casals
Wantuch, Slawomir
Normantaite, Deimante
Leach, Martin O.
Whittaker, Steven R.
Beloueche-Babari, Mounia
BRITISH JOURNAL OF CANCER, 2020, 122 (01) : 72 - 81
[36] BRAF inhibition in hairy cell leukemia
Dietrich, S.
Peyrade, F.
Follows, G.
Glimm, H.
Andrulis, M.
Hundemer, M.
von Kalle, C.
Ho, A.
Zenz, T.
ONKOLOGIE, 2013, 36 : 34 - 34
[37] BRAF mutation in hairy cell leukemia
Ahmadzadeh, Ahmad
Shahrabi, Saeid
Jaseb, Kaveh
Norozi, Fatemeh
Shahjahani, Mohammad
Vosoughi, Tina
Hajizamani, Saeideh
Saki, Najmaldin
ONCOLOGY REVIEWS, 2014, 8 (02) : 50 - 53
[38] Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers
Biersack, Bernhard
Nitzsche, Bianca
Hoepfner, Michael
CANCER DRUG RESISTANCE, 2025, 8
[39] Phase I trial evaluating concurrent vemurafenib and ipilimumab in patients with advanced BRAF-mutant melanoma
Ribas, A.
Hodi, F. S.
Callahan, M.
Chmielowski, B.
Lawrence, D.
Konto, C.
McHenry, M. B.
Choong, N.
Wolchok, J.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S867 - S867
[40] Combination of rituximab and vemurafenib in the treatment of Hairy Cell Leukemia
Stocker, Nicolas
HEMATOLOGIE, 2021, 27 (05): : 219 - 219

← 1 2 3 4 5 →